Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.

Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday. A number of other equities ...

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...

Was it simply a fluke that he kept treating strikingly young patients? Or was his practice one tiny data point in a larger trend? He found his answer after sifting through national health data: ...

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.